IQIRVO

This brand name is authorized in United States.

Active ingredients

The drug IQIRVO contains one active pharmaceutical ingredient (API):

1	Elafibranor UNII 2J3H5C81A5 - ELAFIBRANOR
	Elafibranor and its main active metabolite GFT1007 are dual peroxisome proliferator-activated receptor (PPAR)α/δ agonists. PPAR α/δ are thought to be key regulators of bile acid (BA) homeostasis, inflammation and fibrosis. Activation of PPARα and PPARδ decreases bile toxicity and improve cholestasis by modulating BA synthesis, detoxification and transporters. Activation of PPARα and PPARδ also has anti-inflammatory effects by acting on different pathways.
	Read more about Elafibranor

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
IQIRVO Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
IQIRVO Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A05AX06		A Alimentary tract and metabolism → A05 Bile and liver therapy → A05A Bile therapy → A05AX Other drugs for bile therapy
Discover more medicines within A05AX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	15054-0080